Huili Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Huili Feng has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Changwei Qiu
Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Huazhong Agricultural University
5 shared publications - Xiao Wang
Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China
5 shared publications - Ganzhen Deng
Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, People’s Republic of China
4 shared publications - Lixin He
Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China
3 shared publications - Talha Umar
Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China
3 shared publications - Bohan Zhang
Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China
2 shared publications
Latest Publications
- Open Access
- 29 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 403
Synergistic Antitumor Effects of Ivermectin and Metformin in Canine Breast Cancer via PI3K/AKT/mTOR Pathway Inhibition
Ivermectin (IVM) is a macrolide antiparasitic drug, and Metformin (MET) is a biguanide oral hypoglycemic drug. Studies have shown that both of them have obvious anti-tumor effects, but there have been no reports on the combined treatment of Canine breast tumors. This report aimed to investigate the effectiveness and the possible mechanism of drug combination on Canine breast cancers. Mouse breast tumor cells (4T1) and canine breast tumor cells (CMT-1211) were, respectively, treated with IVM, MET, and their combination, and then cell viability was assessed. After that, transcriptomic analysis was performed to study the action pathway of the drug combination with regard to its anti-tumor effects. Reactive oxygen species (ROS) levels were detected by flow cytometry, and autophagosome formation was observed by transmission electron microscopy (TEM). Immunofluorescence detected the cytoplasmic translocation of LC3B and P62 into the nucleus. Western blot detected the protein expressions of LC3B, P62, Beclin1, Bcl-2, p-PI3K, p-AKT, and p-mTOR. Our transcriptomic analysis showed that the combination of IVM and MET regulated the expression of autophagy-related genes and pathways, including the PI3K/AKT/mTOR signaling pathway. Our in vitro experiments showed that the combination of two drugs had a considerably significant effect on cytotoxicity, ROS levels, and the formation of autophagosomes compared to each drug alone. Meanwhile, the in vivo experiments showed that IVM combined with MET had an obvious inhibitory effect on tumor growth in canine breast tumor xenografts. This study concluded that IVM with MET activated autophagy, which killed breast cancer cells by inhibiting the activation of the PI3K/AKT/mTOR pathway and promoting the excessive accumulation of ROS. It offers a theoretical foundation for the synergistic effects of MET and IVM to suppress breast cancer cell activity.
- 29 May 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (6) , 403
Open AccessSynergistic Antitumor Effects of Ivermectin and Metformin in Canine Breast Cancer via PI3K/AKT/mTOR Pathway Inhibition
Ivermectin (IVM) is a macrolide antiparasitic drug, and Metformin (MET) is a biguanide oral hypoglycemic drug. Studies have shown that both of them have obvious anti-tumor effects, but there have been no reports on the combined treatment of Canine breast tumors. This report aimed to investigate the effectiveness and the possible mechanism of drug combination on Canine breast cancers. Mouse breast tumor cells (4T1) and canine breast tumor cells (CMT-1211) were, respectively, treated with IVM, MET, and their combination, and then cell viability was assessed. After that, transcriptomic analysis was performed to study the action pathway of the drug combination with regard to its anti-tumor effects. Reactive oxygen species (ROS) levels were detected by flow cytometry, and autophagosome formation was observed by transmission electron microscopy (TEM). Immunofluorescence detected the cytoplasmic translocation of LC3B and P62 into the nucleus. Western blot detected the protein expressions of LC3B, P62, Beclin1, Bcl-2, p-PI3K, p-AKT, and p-mTOR. Our transcriptomic analysis showed that the combination of IVM and MET regulated the expression of autophagy-related genes and pathways, including the PI3K/AKT/mTOR signaling pathway. Our in vitro experiments showed that the combination of two drugs had a considerably significant effect on cytotoxicity, ROS levels, and the formation of autophagosomes compared to each drug alone. Meanwhile, the in vivo experiments showed that IVM combined with MET had an obvious inhibitory effect on tumor growth in canine breast tumor xenografts. This study concluded that IVM with MET activated autophagy, which killed breast cancer cells by inhibiting the activation of the PI3K/AKT/mTOR pathway and promoting the excessive accumulation of ROS. It offers a theoretical foundation for the synergistic effects of MET and IVM to suppress breast cancer cell activity.
- Open Access
- 16 April 2025
- Published by MDPI AG in Preprints.org
Synergistic Antitumor Effects of Ivermectin and Metformin in Canine Breast Cancer via PI3K/AKT/mTOR Pathway Inhibition
Ivermectin (IVM) is a macrolide antiparasitic drug, and Metformin (MET) is a biguanide oral hypoglycemic drug. Studies have shown that both of them have obvious anti-tumor effects, but there have been no reports on the combined treatment of Canine breast tumors.This report aimed to investigate the effectiveness and the possible mechanism of drug combination on Canine breast cancers. Mouse breast tumor cells (4T1) and canine breast tumor cell (CMT-1211) were respec-tively treated with IVM, MET and their combination, and then cell viability was assessed. After that transcriptomic analysis was performed to study the action pathway of the drug combination on anti-tumor. Reactive oxygen species (ROS) levels were detected by flow cytometry, and au-tophagosome formation was observed by transmission electron microscopy (TEM). Immunoflu-orescence detected the cytoplasmic translocation of LC3B and P62 into the nucleus. Western blot detected the protein expressions of LC3B, P62, Beclin1, Bcl-2, p-PI3K, p-AKT, and p-mTOR. Our transcriptomic analysis showed that the combination of IVM and MET regulated the expression of autophagy-related genes and pathways, including the PI3K/AKT/mTOR signalling pathway. Our in vitro experiments showed that the combination of two drugs had a considerably significant effect on cytotoxicity, ROS levels, and the formation of autophagosomes compared to each drug alone. Meanwhile, in vivo experiments showed that It was observed that IVM combined with MET had obvious inhibitory effect on tumor growth in canine breast tumor xenografts. This study concluded that IVM with MET activated autophagy, which killed breast cancer cells by inhibiting the activation of the PI3K/AKT/mTOR pathway and promoting the excessive accumulation of ROS. It offers a theoretical foundation for the synergistic effects of MET and IVM to suppress breast cancer cell activity.
- 16 April 2025
- Published by MDPI AG in Preprints.org
Open AccessSynergistic Antitumor Effects of Ivermectin and Metformin in Canine Breast Cancer via PI3K/AKT/mTOR Pathway Inhibition
Ivermectin (IVM) is a macrolide antiparasitic drug, and Metformin (MET) is a biguanide oral hypoglycemic drug. Studies have shown that both of them have obvious anti-tumor effects, but there have been no reports on the combined treatment of Canine breast tumors.This report aimed to investigate the effectiveness and the possible mechanism of drug combination on Canine breast cancers. Mouse breast tumor cells (4T1) and canine breast tumor cell (CMT-1211) were respec-tively treated with IVM, MET and their combination, and then cell viability was assessed. After that transcriptomic analysis was performed to study the action pathway of the drug combination on anti-tumor. Reactive oxygen species (ROS) levels were detected by flow cytometry, and au-tophagosome formation was observed by transmission electron microscopy (TEM). Immunoflu-orescence detected the cytoplasmic translocation of LC3B and P62 into the nucleus. Western blot detected the protein expressions of LC3B, P62, Beclin1, Bcl-2, p-PI3K, p-AKT, and p-mTOR. Our transcriptomic analysis showed that the combination of IVM and MET regulated the expression of autophagy-related genes and pathways, including the PI3K/AKT/mTOR signalling pathway. Our in vitro experiments showed that the combination of two drugs had a considerably significant effect on cytotoxicity, ROS levels, and the formation of autophagosomes compared to each drug alone. Meanwhile, in vivo experiments showed that It was observed that IVM combined with MET had obvious inhibitory effect on tumor growth in canine breast tumor xenografts. This study concluded that IVM with MET activated autophagy, which killed breast cancer cells by inhibiting the activation of the PI3K/AKT/mTOR pathway and promoting the excessive accumulation of ROS. It offers a theoretical foundation for the synergistic effects of MET and IVM to suppress breast cancer cell activity.
- Open Access
- 21 February 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (3) , 251
Comparative Transcriptional Analysis of Long Noncoding RNAs in Oxidative Stress and Inflammation Induced by Potassium Permanganate and Lipopolysaccharide in Rat Uterine Tissues
Potassium permanganate (KMnO4) is a commercially available antiseptic used in bovine intrauterine lavage to manage postpartum infections. Lipopolysaccharides (LPS) are well-studied for their ability to induce inflammation and oxidative stress. While KMnO4 is known to cause significant irritation, oxidative stress, and toxicity in uterine tissues, its transcriptional impact and potential for inducing similar molecular damage as LPS have not been fully explored. In this study, we induced oxidative stress in the uterine tissues of Sprague–Dawley (SD) rats using KMnO4 and compared the transcriptional profiles with those treated with LPS. We focused on the differential expression of long noncoding RNAs (lncRNAs) and messenger RNAs (mRNAs) related to oxidative stress, toxicity, and inflammation. RNA sequencing revealed 1125 differentially expressed mRNAs in the KMnO4-treated group and 989 in the LPS-treated group. Additionally, 1649 lncRNAs were differentially expressed in the KMnO4 group compared with 1383 in the LPS group. Gene ontology (GO) and KEGG enrichment analyses showed that 78 pathways were significantly enriched in the KMnO4 group, while 80 pathways were enriched in the LPS group, with 50 pathways shared between the two. This study offers critical insights into the transcriptional profiles associated with KMnO4 exposure and its similarities to LPS-induced damage.
- 21 February 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (3) , 251
Open AccessComparative Transcriptional Analysis of Long Noncoding RNAs in Oxidative Stress and Inflammation Induced by Potassium Permanganate and Lipopolysaccharide in Rat Uterine Tissues
Potassium permanganate (KMnO4) is a commercially available antiseptic used in bovine intrauterine lavage to manage postpartum infections. Lipopolysaccharides (LPS) are well-studied for their ability to induce inflammation and oxidative stress. While KMnO4 is known to cause significant irritation, oxidative stress, and toxicity in uterine tissues, its transcriptional impact and potential for inducing similar molecular damage as LPS have not been fully explored. In this study, we induced oxidative stress in the uterine tissues of Sprague–Dawley (SD) rats using KMnO4 and compared the transcriptional profiles with those treated with LPS. We focused on the differential expression of long noncoding RNAs (lncRNAs) and messenger RNAs (mRNAs) related to oxidative stress, toxicity, and inflammation. RNA sequencing revealed 1125 differentially expressed mRNAs in the KMnO4-treated group and 989 in the LPS-treated group. Additionally, 1649 lncRNAs were differentially expressed in the KMnO4 group compared with 1383 in the LPS group. Gene ontology (GO) and KEGG enrichment analyses showed that 78 pathways were significantly enriched in the KMnO4 group, while 80 pathways were enriched in the LPS group, with 50 pathways shared between the two. This study offers critical insights into the transcriptional profiles associated with KMnO4 exposure and its similarities to LPS-induced damage.
- Open Access
- 6 December 2024
- Published by MDPI AG in Preprints.org
Comparative Transcriptional Analysis of Long Noncoding RNAs in Oxidative Stress and toxicology Induced by Potassium Permanganate and Lipopolysaccharide in Rat Uterine Tissues
Potassium permanganate (KMnO₄) is a commercially available antiseptic used in bovine intrauterine lavage to manage postpartum infections. Lipopolysaccharides (LPS) are well-studied for their ability to induce inflammation and oxidative stress. While KMnO₄ is known to cause significant irritation, oxidative stress, and toxicity in uterine tissues, its transcriptional impact and potential for inducing similar molecular damage as LPS have not been fully explored. In this study, we induced oxidative stress in the uterine tissues of Sprague Dawley (SD) rats using KMnO₄ and compared the transcriptional profiles with those treated with LPS. We focused on the differential expression of long noncoding RNAs (lncRNAs) and messenger RNAs (mRNAs) related to oxidative stress, toxicity, and inflammation. RNA sequencing revealed 1125 differentially expressed mRNAs in the KMnO₄-treated group and 989 in the LPS-treated group. Additionally, 1649 lncRNAs were differentially expressed in the KMnO₄ group compared to 1383 in the LPS group. Gene ontology (GO) and KEGG enrichment analyses showed that 78 pathways were significantly enriched in the KMnO₄ group, while 80 pathways were enriched in the LPS group, with 50 pathways shared between the two. This study offers critical insights into the transcriptional profiles associated with KMnO₄ exposure and its similarities to LPS-induced damage.
- 6 December 2024
- Published by MDPI AG in Preprints.org
Open AccessComparative Transcriptional Analysis of Long Noncoding RNAs in Oxidative Stress and toxicology Induced by Potassium Permanganate and Lipopolysaccharide in Rat Uterine Tissues
Potassium permanganate (KMnO₄) is a commercially available antiseptic used in bovine intrauterine lavage to manage postpartum infections. Lipopolysaccharides (LPS) are well-studied for their ability to induce inflammation and oxidative stress. While KMnO₄ is known to cause significant irritation, oxidative stress, and toxicity in uterine tissues, its transcriptional impact and potential for inducing similar molecular damage as LPS have not been fully explored. In this study, we induced oxidative stress in the uterine tissues of Sprague Dawley (SD) rats using KMnO₄ and compared the transcriptional profiles with those treated with LPS. We focused on the differential expression of long noncoding RNAs (lncRNAs) and messenger RNAs (mRNAs) related to oxidative stress, toxicity, and inflammation. RNA sequencing revealed 1125 differentially expressed mRNAs in the KMnO₄-treated group and 989 in the LPS-treated group. Additionally, 1649 lncRNAs were differentially expressed in the KMnO₄ group compared to 1383 in the LPS group. Gene ontology (GO) and KEGG enrichment analyses showed that 78 pathways were significantly enriched in the KMnO₄ group, while 80 pathways were enriched in the LPS group, with 50 pathways shared between the two. This study offers critical insights into the transcriptional profiles associated with KMnO₄ exposure and its similarities to LPS-induced damage.
- Open Access
2’-Hydroxychalcone Induces Autophagy and Apoptosis in Breast Cancer Cells via the Inhibition of the NF-κB Signaling Pathway: In Vitro and In Vivo Studies
2’-Hydroxychalcone is a hydroxyl derivative of chalcones, which are biosynthetic precursors of flavonoids and rich in the human diet. The anticancer activity of 2’-hydroxychalcone has been reported in several cancers but remains to be investigated in breast cancer. In the current study, 2’-hydroxychalcone showed significant cytotoxicity against breast cancer cell lines MCF-7 and CMT-1211. It could inhibit breast cancer cell proliferation, migration, and invasion in vitro and suppress tumor growth and metastasis in vivo. Mechanistic investigation revealed that the NF-κB pathway was significantly inhibited by 2’-hydroxychalcone treatment accompanied by an excessive intracellular accumulation of reactive oxygen species, induction of endoplasmic reticulum stress, and activation of JNK/MAPK. In addition, 2’-hydroxychalcone elevated the autophagic levels in breast cancer cells equipped with increasing numbers of autophagy vesicles and complete autophagic flux. Finally, autophagy-dependent apoptosis was observed in 2’-hydroxychalcone-induced cell death. In conclusion, 2’-hydroxychalcone enhances the autophagic levels and induces apoptosis in breast cancer cells, which could be contributed to the inhibition of the pro-survival NF-κB signaling, indicating a promising potential for 2’-hydroxychalcone in future anticancer drug development.
Open Access2’-Hydroxychalcone Induces Autophagy and Apoptosis in Breast Cancer Cells via the Inhibition of the NF-κB Signaling Pathway: In Vitro and In Vivo Studies
2’-Hydroxychalcone is a hydroxyl derivative of chalcones, which are biosynthetic precursors of flavonoids and rich in the human diet. The anticancer activity of 2’-hydroxychalcone has been reported in several cancers but remains to be investigated in breast cancer. In the current study, 2’-hydroxychalcone showed significant cytotoxicity against breast cancer cell lines MCF-7 and CMT-1211. It could inhibit breast cancer cell proliferation, migration, and invasion in vitro and suppress tumor growth and metastasis in vivo. Mechanistic investigation revealed that the NF-κB pathway was significantly inhibited by 2’-hydroxychalcone treatment accompanied by an excessive intracellular accumulation of reactive oxygen species, induction of endoplasmic reticulum stress, and activation of JNK/MAPK. In addition, 2’-hydroxychalcone elevated the autophagic levels in breast cancer cells equipped with increasing numbers of autophagy vesicles and complete autophagic flux. Finally, autophagy-dependent apoptosis was observed in 2’-hydroxychalcone-induced cell death. In conclusion, 2’-hydroxychalcone enhances the autophagic levels and induces apoptosis in breast cancer cells, which could be contributed to the inhibition of the pro-survival NF-κB signaling, indicating a promising potential for 2’-hydroxychalcone in future anticancer drug development.